GSWM
ALXN

Golden State Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Golden State Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2
Closed – – 1004
2020
Q1 		$0 Buy
+2
New +$196 ﹤0.01% 1021
2019
Q4 		– Sell
-2
Closed – – 1062
2019
Q3 		$0 Hold
2
– – ﹤0.01% 1161
2019
Q2 		$0 Buy
+2
New +$258 ﹤0.01% 1179

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Golden State Wealth Management's ALXN Position: Q2 2020 in Review

Golden State Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 2 shares.

Golden State Wealth Management first reported a position in ALXN in Q2 2019 and held it in 3 quarters. The position peaked at $0 in Q1 2020. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Golden State Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Golden State Wealth Management sold 2 Alexion Pharmaceuticals shares in Q2 2020.
  • Golden State Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Golden State Wealth Management's Alexion Pharmaceuticals position peaked at $0 in Q1 2020.
  • 705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Golden State Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.